Kornimate/medical-research-clean huggingface dataset:
prefers (preserved and reduced ejection fraction epidemiological regional study) stockholm heart failure study

Conditions: Heart Failure, Diastolic; Heart Failure，Congestive

Summary: heart failure (hf) with preserved (hfpef) or reduced (hfref) ejection fraction is associated with poor prognosis and quality of life. while the incidence of hfref is declining and hf treatment is effective, hfpef is increasing, with no established therapy. prefers stockholm is an epidemiological study with the aim of improving clinical care and research in hf and to find new targets for drug treatment in hfpef starting with a cardiac biopsy study in elective cabg patiens.

patients with new-onset hf (n = 2000) will be characterized at baseline and after 1-year follow-up by standardized protocols for clinical evaluation, echocardiography, and ecg. in one subset undergoing elective coronary bypass surgery (n = 100) and classified according to lv function, myocardial biopsies will be collected during surgery, and cardiac magnetic resonance (cmr) imaging will be performed at baseline and after 1 year. blood and tissue samples will be stored in a biobank.we will characterize and compare new-onset hfpef and hfref patients regarding clinical findings and cardiac imaging, genomics, proteomics, and transcriptomics from blood and cardiac biopsies, and by established biomarkers of fibrosis, inflammation, haemodynamics, haemostasis, and thrombosis. the data will be explored by state-of-the-art bioinformatics methods to investigate gene expression patterns, sequence variation, dna methylation, and post-translational modifications, and using systems biology approaches including pathway and network analysis.in this epidemiological hf study with biopsy studies in a subset of patients, we aim to identify new biomarkers of disease progression and to find pathophysiological mechanisms to support explorations of new treatment regimens for hfpef.

Eligibility criteria:
inclusion criteria:cabg prefers inclusion criteria: 1. patients undergoing elective coronary bypass surgery 2. history of heart failure not required 3. age \>18 years 4. willingness to participate (written informed consent) 5. possibility to obtain technically satisfactory echocardiography inclusion criteria prefers: 1. new-onset heart failure according to esc guidelines including nt-probnp \>125 ng/l at heart failure clinic or \>300 ng/l at emergency department visit or hospital admission 2. age \>18 years 3. willingness to participate (written informed consent) 4. possibility to obtain technically satisfactory echocardiography exclusion criteria cabg prefers and prefers: 1. cognitive impairment 2. inability to understand swedish language 3. anaemia (haemoglobin level \<90 g/l) 4. heart failure primarily due to valvular disease, primary right ventricular failure, pulmonary artery hypertension, hypertrophic obstructive cardiomyopathy infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis, or haemochromatosis) 5. severe co-morbidity, severe copd, severe renal dysfunction (egfr \<30 ml/min/1.73m2). any other co-morbid disease that will disable the ability to assess or treat heart failure.
study of blood samples and risk of infection in patients with newly diagnosed malignant supratentorial astrocytoma

Conditions: Brain and Central Nervous System Tumors; Infection

Summary: rationale: gathering information over time from laboratory tests of patients with newly diagnosed malignant supratentorial astrocytoma may help doctors learn more about the effect of treatment on white blood cell count and the risk of infection. purpose: this clinical trial is studying blood samples and risk of infection in patients with newly diagnosed malignant supratentorial astrocytoma.

objectives: * determine the frequency and severity of decreases in cd4 counts as a function of therapy in patients with newly diagnosed malignant astrocytoma. * determine whether the decrease in cd4 counts is a significant predictor of infections or adverse outcomes in these patients. outline: this is a multicenter study. patients undergo monthly collection of blood for serial cd4 counts and heme-8 with differential for 1 year for quantitative analysis. patients also complete a monthly questionnaire about infections and antibiotic use. patients are followed every 2 months. projected accrual: a total of 125 patients (100 with high-grade disease and 25 with low-grade disease) will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed primary malignant brain tumor in 1 of the following groups: * high grade (grade iii or iv) supratentorial glioma receiving antineoplastic treatment and with 1 of the following histologies: * anaplastic astrocytoma * glioblastoma multiforme (giant cell glioblastoma or gliosarcoma) * anaplastic oligodendroma * low grade (grade i or ii) supratentorial glioma not planning to receive treatment of any kind (including steroids) and with 1 of the following histologies: * astrocytoma * oligodendroglioma patient characteristics: * karnofsky performance status 60-100% * no hiv positivity prior concurrent therapy: * no prior chemotherapy for brain tumor except polifeprosan 20 with carmustine implant (gliadel® wafer) * no prior cranial radiotherapy or radiotherapy for brain tumor * no prior immunotherapy or biologic agents for brain tumor, including any of the following: * immunotoxins * immunoconjugates * peptide receptor antagonists * interleukins * interferons * tumor-infiltrating lymphocytes * lymphokine-activated killer cell therapy * gene therapy * antisense therapy * no prior hormonal therapy for brain tumor * more than 14 days since prior and no concurrent steroid therapy for patients with low-grade (grade i or ii) astrocytoma * prior glucocorticoid therapy allowed

Keywords: infection adult anaplastic astrocytoma adult anaplastic oligodendroglioma adult giant cell glioblastoma adult gliosarcoma adult oligodendroglioma adult glioblastoma adult diffuse astrocytoma adult pilocytic astrocytoma adult pineal gland astrocytoma adult subependymal giant cell astrocytoma
interaction between chlorhexidine and fluoride

Conditions: Periodontal Disease; Dental Caries

Summary: the aim of the present study was to study if there are interactions and reduced clinical effect between chlorhexidine and fluoride when they are combined in the same mouthrinse.

the investigation assessed the clinical effect of a mouthrinse containing chlorhexidine (chx) and sodium fluoride (naf) during a 4-day period of non-brushing and a 6-week period of brushing. two studies were designed as double-blind, randomized, cross-over clinical trials. in study i, 16 healthy subjects rinsed twice daily for 1 min during 4 days of no tooth brushing with four mouthrinse solutions: 1) 0.12% chx + 0.2% naf, 2) 0.2% naf, 3) 0.12% chx, and 4) placebo. in study 2, 16 healthy subjects rinsed with the same four solutions twice daily after tooth brushing during a 6-week period. primary outcomes were plaque formation and gingivitis. secondary outcomes were fluoride retention and microbiological parameters in plaque and saliva (total bacterial counts and mutans streptococci, lactobacilli and streptococci sanguinis counts). one way analyses of variance with post hoc student-newman-keul´s statistical test was performed for comparisons between mouthrinses. intragroup changes over time were analyzed with a paired t-test.

Eligibility criteria:
inclusion criteria: * male and female subjects, age 18-35 years * good general health * no signs of periodontitis and caries * a minimum of 24 teeth with no extensive restorations * no current or planned dental treatment during the trial periods. exclusion criteria: * antibiotic treatment within 1 month prior to the start of the trial * current medication with anti-inflammatory drugs * use of antiseptic mouthrinses * smokers and snuff user * use of chewing gums

Keywords: prevention
dna cdo1 and celf4 methylation for endometrial cancer screening

Conditions: Endometrial Cancer; Cancer Screening; DNA Methylation; Testing Accuracy; Cervical Cytology

Summary: based on the previous study of nct04651738, we performed this trial to further confirm the accuracy of host dna cdo1 and celf4 methylation for endometrial cancer screening. this study would provide profound basis for the approval of assay kit of dna methylation in china for endometrial screening. four hospitals, including peking union medical college hospital, would enroll eligible patients in this study. the cervical cytology of 3 ml will be collected for the detection of dna cdo1 and celf4 methylation, and the results will compared with the endometrial histological pathology, which is achieved after collection of cervical cytology, by surgeries including hysteroscopy, dilation and curettage, total hysterectomy and others. the methylation testing would be double-blinded in operators and analysts. the study will enroll at least 7150 patients.


Eligibility criteria:
inclusion criteria: * with uerine and uterine cervix intact * aged 18 years or older * with accessible histological results of endometrium * signed an approved informed consents * with accessible cervical cytology before harvesting endometrial histology exclusion criteria: * not meeting all of the inclusion criteria
a study of ad26.cov2.s for the prevention of sars-cov-2-mediated covid-19 in adult participants

Conditions: Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol

Summary: the study will evaluate the efficacy of ad26.cov2.s in the prevention of molecularly confirmed moderate to severe/critical covid-19, as compared to placebo, in adult participants.


Eligibility criteria:
inclusion criteria: * contraceptive (birth control) use should be consistent with local regulations regarding the acceptable methods of contraception for those participating in clinical studies * all participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration * participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine * must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study * must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (ecoa) (that is, the coronavirus disease-2019 \[covid 19\] signs and symptoms surveillance question, the e-diary, and the electronic patient-reported outcomes (epros). note: participants with visual impairment are eligible for study participation and may have caregiver assistance in completing the electronic clinical outcome assessment (ecoa) questionnaires exclusion criteria: * participant has a clinically significant acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature greater than or equal to (\>=) 38.0 degree celsius (100.4-degree fahrenheit) within 24 hours prior to the planned first dose of study vaccine; randomization at a later date is permitted at the discretion of the investigator and after consultation with the sponsor * participant received or plans to receive: (a) licensed live attenuated vaccines - within 28 days before or after planned administration of study vaccine ; and (b) other licensed (not live) vaccines - within 14 days before or after planned administration of study vaccine * participant previously received a coronavirus vaccine * participant received an investigational drug (including investigational drugs for prophylaxis of covid-19) within 30 days or used an invasive investigational medical device within 30 days or received investigational immunoglobulin (ig) or monoclonal antibodies within 3 months, or received convalescent serum for covid-19 treatment within 4 months or received an investigational vaccine (including investigational adenoviral-vectored vaccines) within 6 months before the planned administration of the first dose of study vaccine or is currently enrolled or plans to participate in another investigational study during the course of this study

Keywords: prevention vaccine
physical activity augmentation using pedometers during pulmonary rehabilitation in chronic obstructive pulmonary disease

Conditions: Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic

Summary: patients with chronic lung diseases such as chronic obstructive pulmonary disease (copd), who perform regular physical activity, have improved health and wellbeing compared with those who do little exercise. the purpose of the study is to evaluate whether the use of a simple pedometer (step counter) to set targets for daily physical activity can encourage copd patients referred for an 8-week pulmonary exercise based programme (pr) to be more active. the investigators also want to know whether the use of pedometers during pr can improve adherence, self-management and outcome in copd.


Eligibility criteria:
inclusion criteria: * all patients with copd exclusion criteria: * any patient in whom mobility and lower limb function have been significantly affected by a neuromuscular disease, severe peripheral vascular disease or amputation * any patient whom the chief investigator feels it is unsafe to exercise (eg. unstable cardiac disease)

Keywords: treatment outcome [e01.789.800] rehabilitation [n02.421.784] physical fitness [i03.621] lung diseases, obstructive [c08.381.495] pulmonary disease, chronic obstructive [c08.381.495.389] bronchitis, chronic [c08.381.495.389.500]
postcath radial arterial clamp time in the cath lab

Conditions: Coronary Artery Disease

Summary: the investigators will assess the effect of different times of radial clamp post procedure on radial artery occlusion and bleeding.

the purpose of this study is to determine the safety of shorter radial artery clamp time post cardiac catheterization with respect to achieving hemostasis and the incidence of radial artery occlusion. the investigators hypothesize that shorter radial artery clamp times following cardiac catheterization will achieve similar hemostasis to longer clamp times with a decrease in the incidence of radial artery occlusion.

Eligibility criteria:
inclusion criteria: * all patients who require cardiac catheterization via the radial approach for the investigation and treatment of coronary artery disease. * patients must have evidence of pre-procedural radial artery patency using barbeau test. * patients must be able to give informed consent exclusion criteria: * evidence of pre-procedural radial artery thrombosis * inability to give informed consent * patient desire not to participate in the study * emergent procedures when the delay associated for obtaining informed consent may affect patient outcome
grinch: groningen initiative on reference intervals in children

Conditions: Inflammatory Bowel Disease

Summary: the purpose of this study is to establish reliable reference intervals for fecal s100a12 in healthy children.

rationale s100a12 (calgranulin c) is a cytoplasmic protein secreted exclusively by activated neutrophils. it can be measured in stools and elevated levels are observed in children with inflammatory bowel disease. the protein is stable in stool samples for up to seven days at room temperature, which allows collection at home and potential delays in transport to the laboratory. s100a12 could be used as a marker to discriminate between pediatric inflammatory and functional gastro-intestinal conditions, and prevent children with a low probability of inflammation from unnecessary endoscopic procedures. until now a reliable reference interval for healthy children is lacking. objective to establish reliable reference intervals for fecal s100a12 in healthy children. time frame healthy children will be asked to send in one feces sample anonymously during the inclusion period. the investigators expect that the required 120 samples will be collected before december 2015. there will be no follow up of patients.

Eligibility criteria:
inclusion criteria healthy volunteers: * age: 6-18 years old exclusion criteria: * treated for any gastro-intestinal symptoms * diarrhea in the last week before the collection of the feces sample * fever in the last week before collection of the feces sample * use of nsaids of proton pump inhibitors in the last 14 days before collection feces sample.
a multi-centre clinical study in chronic spinal cord injury patients

Conditions: Spinal Cord Injuries

Summary: to establish a solid foundation, e.g. network and a coordinating centre for testing new sci therapies in forthcoming randomized controlled multi-centre clinical trials following international standards and guidelines


Eligibility criteria:
inclusion criteria: 1. male or female adult subjects, 18 to 60 years of age; 2. have a clinical diagnosis of chronic sci (defined as a history of ≥ 12 months suffering sci); 3. the diagnosis of sci was confirmed by mri; and 4. voluntarily signs and dates an informed consent form, approved by an institutional review board (irb)/independent ethics committee (iec), prior to any study-specific procedures exclusion criteria: 1. severe head injury; 2. is medically or mentally unstable according to the judgement of the investigator; 3. history of multiple sclerosis or peripheral demyelinating disease; 4. likely to have experimental therapy; 5. any criteria, which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol
tracheostomy in icu with a double lumen endotracheal tube

Conditions: Acute Respiratory Failure; Heart Failure; Neurological Disease

Summary: percutaneous tracheostomy in intensive care unit (icu) is performed with the use of flexible fiberoptic bronchoscope inside the conventional single lumen endotracheal tube owned by the patients. this situation may lead to many disadvantages for ventilation and airway protection of critically ill patients during the procedures. the use of double lumen endotracheal tube dedicated to the percutaneous tracheostomies may: 1. improve the ventilation of patients during the procedure, 2. protect the posterior tracheal wall from damage related to the different step of tracheostomies, 3. protect the lungs from blood and secretions coming down from the chosen site of tracheostomy. so the aim of this study is to evaluate the oxygenation, gas exchange, ventilation and complications of percutaneous tracheostomies performed in icu with a dedicated double lumen endotracheal tube.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years and at least one of following criteria: * prolonged endotracheal intubation * prolonged mechanical ventilation * difficult/prolonged weaning * inability to protect the airway exclusion criteria: * infection of neck tissues * previous surgical neck interventions * recent surgical interventions or fracture of the cervical spine

Keywords: bedside percutaneous tracheostomy intensive care unit dedicated double-lumen tube ineffective airway clearance weaning failure
clinical trial: effectiveness and efficiency of physical exercise in cancer patients

Conditions: Non-Small-Cell Lung Carcinoma; Digestive System Neoplasms; Breast Neoplasms

Summary: aim: to evaluate the effectiveness and efficiency of an innovative exercise program (ep) for patients during treatment for gastrointestinal tumors, breast and non small cells lung cancer, in terms of improved quality of life (qol), fatigue and functional capacity respect the usual standard treatment (st). design: pragmatic randomized clinical trial in two parallel groups: ep and st. setting: 7 primary health centers (phc) of the rediappisciii, in coordination with oncology services. participants: 250 patients with the above tumors, locally advanced or with metastatic disease, in adjuvant treatment, with performance status(ps) ps1-ps0. intervention: both groups received standardized usual care. the ep group will receive, in addition, a nurse supervised exercise program for 2 months in the phc and a second phase in community facilities during the remaining 10 months. measurements: the primary outcome measure is the change from baseline in the qol+66 treatment, as measured by the specific questionnaire for patients with cancer eortc qlq-c-30 and short form(sf-36) overall. secondary: fatigue (facit-f), radiological response, functional capacity (6 minutes walking and cardiopulmonary test), muscle strength and progression-free survival and overall. predictors and confounders: age, sex, stage and tumor type, histology, treatment. analysis: we will compare between groups mean changes from baseline measurement of quality of life questionnaire (qol) and other variables, on an intention to treat basis, using longitudinal mixed-effects models for repeated measures at 2, 6 and 12 months follow-up. cost / effectiveness and cost / incremental utility associated to the program wil be estimated.


Eligibility criteria:
inclusion criteria: * age between 18-70 years * diagnosis of digestive system cancer , breast cancer or histologically confirmed nsclc stage iv physical status (ps) 0 or 1. * first-line chemotherapy treatment for each type of standard tumor * adequate renal, liver and blood function. exclusion criteria: * brain metastases * risk of fracture (bone metastases) * unstable heart disease, uncontrolled bp systolic blood pressure((sbp)\> 200 or diastolic blood pressure (dbp)\> 110), heart failure (nyha ii or greater), constrictive pericarditis * other diseases at the discretion of the investigator to be a contraindication for physical exercise. * perform regular physical activity (150 minutes / week of moderate or vigorous 75)

Keywords: physical exercise health related quality of life non-small-cell lung carcinoma digestive system neoplasms breast neoplasms